知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

259 条记录 (耗时 0.028 秒)

    COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR
    1.
    发明公开
    COMPOSITIONS AND METHODS FOR DELAYING THE INCIDENCE OF LABOR 审中-公开

    公开(公告)号：US20230372306A1

    公开(公告)日：2023-11-23

    申请号：US18083326

    申请日：2022-12-16

    申请人： XOMA (US) LLC

    发明人： Jean-Pierre GOTTELAND ,  Oliver POHL

    IPC分类号： A61K31/426 ,  A61P15/06 ,  A61K31/573 ,  A61K31/4422

    CPC分类号： A61K31/426 ,  A61P15/06 ,  A61K31/573 ,  A61K31/4422

    摘要： The invention provides compositions and methods for delaying the onset of delivery in a pregnant subject, such as a pregnant human subject, that is undergoing or at risk of undergoing preterm labor at a gestational age of from about 24 weeks to about 34 weeks. Using the compositions and methods described herein, such subjects may be administered nifedipine in combination with a prostaglandin F2α (PGF2α) antagonist. Exemplary PGF2α receptor antagonists that may be used for the treatment or prevention of preterm labor as described herein include 1,3-thiazolidine-2-carboxamide compounds, such as (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate or a pharmaceutically acceptable salt thereof (e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate hydrochloride. Using the compositions and methods described herein, a subject may be dosed with a PGF2α receptor antagonist and a reduced amount or frequency of nifedipine relative to the amount or frequency of nifedipine that would otherwise be used if the nifedipine were given in the absence of the PGF2α receptor antagonist.

    Carrier status of annexin A5 M2 haplotype and obstetric risks
    8.
    发明授权
    Carrier status of annexin A5 M2 haplotype and obstetric risks 有权

    公开(公告)号：US10925891B2

    公开(公告)日：2021-02-23

    申请号：US15302340

    申请日：2015-04-07

    申请人： IHG Pharmaco Limited

    发明人： Deborah Jane Baker

    IPC分类号： A61K31/727 ,  C12Q1/6883 ,  A61P15/06 ,  C12Q1/6876

    摘要： The present invention relates to determining the carrier status of Annexin A5 M2 haplotype of parents (both male and female) prior to and/or after pregnancy to minimize the risk of pregnancy complications, including, but not limited to, recurrent pregnancy loss (RPL), infertility, miscarriage, in vitro fertilization (IVF) failure, IUI failure, implantation failure, foetal growth restriction (FGR), small for gestational age (SGA) newborn, intra-uterine foetal death (IUFD), gestational hypertension (GH), pre-eclampsia (PE) and/or venous thromboembolism (VTE). Once M2 carrier status is determined, methods of intervention, including administration of low molecular weight heparin (LMWH) and/or other anti-coagulants can be administered either prior to and/or after pregnancy. Methods of detecting the carrier status as well as method of diagnosing and or predicting prognosis based on the M2 carrier status of a patient and/or couple is also contemplated.